Aktis Oncology, Inc. (AKTS)

Aktis Oncology Stock Forecast

Stock Price Forecast

According to 6 analysts polled by S&P Global, Aktis Oncology stock has a consensus rating of "Strong Buy" and an average price target of $32.25. The average 1-year stock price forecast is 64.96% higher than the current stock price, while the lowest is $30 (+53.45%) and the highest is $34 (+73.91%).

Price Target: $32.25 (+64.96%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$30	$32.25	$33	$34
Change	+53.45%	+64.96%	+68.80%	+73.91%

* Price targets were last updated on Mar 31, 2026.

Analyst Ratings

The average analyst rating for Aktis Oncology stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Dec '25	Jan '26	Feb '26	Mar '26	Apr '26	May '26
Strong Buy	1	1	0	1	1	1
Buy	1	1	1	1	2	2
Hold	2	2	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	4	4	1	2	3	3

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Alexandra Ramsey William Blair	William Blair	Buy Initiates n/a	Buy	Initiates	n/a	n/a	Apr 29, 2026
Robert Burns HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Maintains $30 → $33	Strong Buy	Maintains	$30 → $33	+68.80%	Mar 31, 2026
Robert Burns HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Initiates $30	Strong Buy	Initiates	$30	+53.45%	Mar 9, 2026
Jessica Fye JP Morgan	JP Morgan	Buy Initiates $30	Buy	Initiates	$30	+53.45%	Feb 3, 2026
Harsh Kumar Piper Sandler	Piper Sandler	Buy → Hold Downgrades $2 → $1	Buy → Hold	Downgrades	$2 → $1	-94.88%	Jan 4, 2024

More Analyst Ratings

Financial Forecast

Revenue This Year

17.30M

Increased by 166.26%

from 6.50M

Revenue Next Year

18.18M

Increased by 5.10%

from 17.30M

EPS This Year

-1.57

from -78.34

EPS Next Year

-1.84

from -1.57

Fiscal Year	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027	FY 2028
Period Ending	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027	Dec 31, 2028
Revenue	-	-	1.49M	6.50M	17.30M	18.18M	3.06M
Revenue Growth	-	-	-	336.92%	166.26%	5.10%	-83.17%
EPS	-34.65	-46.55	-62.46	-78.34	-1.57	-1.84	-2.64
EPS Growth	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-
No. Analysts	-	-	-	-	8	8	4

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2026	2027	2028	2029	2030	2031	2032	2033
High	52.5M	42.0M
Avg	17.3M	18.2M
Low	n/a	5.9M

Revenue Growth

Revenue Growth	2026	2027	2028	2029	2030	2031	2032	2033
High	708.1%	142.8%
Avg	166.3%	5.1%
Low	-	-66.0%

EPS Forecast

EPS	2026	2027	2028
High	-1.27	-1.10
Avg	-1.57	-1.84
Low	-1.69	-2.30

EPS Growth

EPS Growth	2026	2027	2028
High	-	-
Avg	-	-
Low	-	-

Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.